Fulgent Genetics to Announce Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 28, 2023

Rhea-AI Summary

Fulgent Genetics, Inc. (NASDAQ: FLGT) announced it will release its fourth quarter and full year 2022 financial results after market close on February 28, 2023. A conference call will follow at 4:30 PM ET to discuss the results with investors. Fulgent is a technology-based genetic testing company focused on oncology, infectious and rare diseases, reproductive health, and pathology. Their proprietary platform offers a flexible test menu, aiming to enhance patient care while maintaining competitive pricing and turnaround times. The company is transitioning to a fully integrated precision medicine company.

Positive

• Plans to release fourth quarter and full year 2022 financial results on February 28, 2023.
• Focus on transforming into a fully integrated precision medicine company.

Negative

• None.

TEMPLE CITY, Calif.--(BUSINESS WIRE)-- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based genetic testing and therapeutics company focused on transforming patient care in oncology, infectious and rare diseases, reproductive health, and pathology, today announced that it will release its fourth quarter and full year 2022 financial results after the market closes on Tuesday, February 28, 2023. Management will host a conference call for the investment community the same day at 4:30 PM ET (1:30 PM PT) to discuss the results and answer questions.

The call may be accessed through a live audio webcast on the Investor Relations section of the company’s website, http://ir.fulgentgenetics.com. An audio replay will be available at the same location.

About Fulgent

Fulgent is a technology-based genetic testing and therapeutics company focused on transforming patient care in oncology, infectious and rare diseases, reproductive health, and pathology. Its proprietary technology platform for genetics has created a broad, flexible test menu and the ability to continually expand and improve its proprietary genetic reference library while maintaining accessible pricing, high accuracy, and competitive turnaround times. Fulgent’s therapeutics business is fully focused on developing drug candidates for treating a broad range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company aims to transform from a genomic diagnostic business into a fully integrated precision medicine company focused on oncology.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230214005675/en/

Investor Relations Contact:

The Blueshirt Group

Melanie Solomon, melanie@blueshirtgroup.com

Source: Fulgent Genetics, Inc.

FAQ

When will Fulgent Genetics release its Q4 2022 financial results?

Fulgent Genetics will release its fourth quarter and full year 2022 financial results on February 28, 2023.

What time is the Fulgent Genetics conference call?

The Fulgent Genetics conference call will take place at 4:30 PM ET on February 28, 2023.

What is the focus of Fulgent Genetics?

Fulgent Genetics focuses on genetic testing and therapeutics for oncology, infectious diseases, rare diseases, reproductive health, and pathology.

What technology does Fulgent Genetics use?

Fulgent Genetics utilizes a proprietary technology platform for genetic testing that offers a broad test menu and competitive turnaround times.

What transition is Fulgent Genetics undergoing?

Fulgent Genetics is transitioning from a genomic diagnostic business to a fully integrated precision medicine company focused on oncology.